Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

8.410 -0.060 (-0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
News headline image
BioCryst Pharmaceuticals Stock Is Tumbling: What's Going On? ↗
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday after the company announced preliminary fourth-quarter and full 
Via Benzinga
News headline image
TSLA Stock Price Prediction: What to Know as Analysts Slash Tesla Price Targets ↗
Tesla (TSLA) stock is in the news as price predictions continue to be a hot topic among traders after Elon Musk's Twitter purchase. 
Via InvestorPlace
News headline image
BioCryst Shelves Development Of Rare Blood Disorder Candidate ↗
 
Via Benzinga
News headline image
Expert Ratings for BioCryst Pharmaceuticals ↗
Analysts have provided the following ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) within the last quarter: 
Via Benzinga
News headline image
Why Is Getaround (GETR) Stock Up 6% Today? ↗
Getaround (GETR) stock is on the move Thursday with heavy trading despite a lack of recent news concerning the car-sharing service. 
Via InvestorPlace
News headline image
BCRX Stock Sinks as BioCryst Discontinues Drug Development ↗
BioCryst Pharmaceuticals (BCRX) stock is falling on Thursday after revealing it's no longer developing BCX9930 for competitive reasons. 
Via InvestorPlace
News headline image
Novavax, Tesla, Western Digital And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 ↗
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
News headline image
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript ↗
BCRX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
4 Analysts Have This to Say About BioCryst Pharmaceuticals ↗
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
News headline image
What's Going On With BioCryst Pharmaceuticals Stock Today? ↗
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported third-quarter financial results. 
Via Benzinga
News headline image
BioCryst Pharmaceuticals: Q3 Earnings Insights ↗
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
News headline image
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap ↗
The company scrapped its hereditary angioedema drug due to safety issues. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy Now for Extraordinary Gains ↗
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
News headline image
BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate ↗
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BioCryst’s (NASDAQ: BCRX) lead asset BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP). 
Via Benzinga
News headline image
Recap Of Friday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
BioCryst Exhibits Positive Data From Early-Stage Rare Kidney Disease Study ↗
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that its lead asset BCX9930 has demonstrated >99 percent suppression of the alternative pathway (AP), and that >98 percent suppression was maintained... 
Via Benzinga
News headline image
US Government To Purchase Additional Influenza Treatment From BioCryst For Pandemic Preparedness ↗
 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Novavax, Upstart Holdings And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗
Novavax, Inc. (NASDAQ: NVAX) fell 30.7% to $39.70 in pre-market trading after the company reported second-quarter revenue decline of 37.6% year-over-year to $185.9 million. The company also lowered its... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗
  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.